264 related articles for article (PubMed ID: 23917044)
1. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
Sobhakumari A; Schickling BM; Love-Homan L; Raeburn A; Fletcher EV; Case AJ; Domann FE; Miller FJ; Simons AL
Toxicol Appl Pharmacol; 2013 Nov; 272(3):736-45. PubMed ID: 23917044
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.
Orcutt KP; Parsons AD; Sibenaller ZA; Scarbrough PM; Zhu Y; Sobhakumari A; Wilke WW; Kalen AL; Goswami P; Miller FJ; Spitz DR; Simons AL
Cancer Res; 2011 Jun; 71(11):3932-40. PubMed ID: 21482679
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Fletcher EV; Love-Homan L; Sobhakumari A; Feddersen CR; Koch AT; Goel A; Simons AL
Mol Cancer Res; 2013 Dec; 11(12):1574-84. PubMed ID: 24048704
[TBL] [Abstract][Full Text] [Related]
4. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
5. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
6. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
7. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Dayekh K; Johnson-Obaseki S; Corsten M; Villeneuve PJ; Sekhon HS; Weberpals JI; Dimitroulakos J
Mol Cancer Ther; 2014 Nov; 13(11):2559-71. PubMed ID: 25189541
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
[TBL] [Abstract][Full Text] [Related]
9. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
10. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
Tsien CI; Nyati MK; Ahsan A; Ramanand SG; Chepeha DB; Worden FP; Helman JI; D'Silva N; Bradford CR; Wolf GT; Lawrence TS; Eisbruch A
Head Neck; 2013 Sep; 35(9):1323-30. PubMed ID: 22907806
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
[TBL] [Abstract][Full Text] [Related]
12. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
[TBL] [Abstract][Full Text] [Related]
13. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
[TBL] [Abstract][Full Text] [Related]
14. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
15. EGFR tyrosine kinase inhibitors differentially affect autophagy in head and neck squamous cell carcinoma.
Cai J; Sun M; Ge X; Sun Y
Biochem Biophys Res Commun; 2017 May; 486(4):1027-1033. PubMed ID: 28366635
[TBL] [Abstract][Full Text] [Related]
16. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
[TBL] [Abstract][Full Text] [Related]
17. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
Haddad Y; Choi W; McConkey DJ
Clin Cancer Res; 2009 Jan; 15(2):532-42. PubMed ID: 19147758
[TBL] [Abstract][Full Text] [Related]
18. Grape seed extract targets mitochondrial electron transport chain complex III and induces oxidative and metabolic stress leading to cytoprotective autophagy and apoptotic death in human head and neck cancer cells.
Shrotriya S; Deep G; Lopert P; Patel M; Agarwal R; Agarwal C
Mol Carcinog; 2015 Dec; 54(12):1734-47. PubMed ID: 25557495
[TBL] [Abstract][Full Text] [Related]
19. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
20. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
